Obermatt

Fagron

BRU:FAGR · BE0003874915
Health Care Providers & ServicesMedium

360

86
EV / EBIT64
Price / Owner Earnings35
Owner Earnings Yield71
Dividend Yield73
Price/Sales72
EV / Gross Profit60
Price/Book51
Return on Capital83
Cash Return on Capital82
Return on Equity86
EBIT Margin95
Gross Profitability79
Cash Conversion50
Accruals23
Owner Earnings Margin84
Sales growth78
Profit Growth57
Long-Term EPS Growth15
Owner Earnings Growth55
Reinvestment92
Price momentum60
Debt load29
Refinancing69
Debt Payback55
Liquidity60
Analyst ratings100
Opinion Changes50
Price Target Upside35
Market mood39
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Fagron generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryBelgium
IndustryHealth Care Providers & Services
SizeMedium
TypePublic Company
ExchangeENXTBR
Founded2007
Employees721
Websitefagron.com
ISINBE0003874915
Last UpdateApr 2, 2026
Index & Theme
ImmunologyDermatology

Description

Fagron NV a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. Business Segments The company categorizes its operations into three primary segments: Essentials, B…

Analysis

Quality compounder

Fagron NV is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is fair. You pay 18.0× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Jun 2026

All-time low

3

Jan 2023

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
72
17
23
28
Price/Earnings
42
47
51
66
Price/Book
51
29
43
41
Dividend Yield
73
49
43
26
Value (overall)
73
20
26
23

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Fagron with its peers
Cegedim
PAR:ALCGM
65
CountryFrance
IndustryHealth Care Technology
SizeSmall
Full Stock Analysis →
Immunovant
NSQ:IMVT
86
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sanofi India
NSI:SANOFI
56
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Jazz Pharmaceuticals
NSQ:JAZZ
91
CountryIreland
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
GlaxoSmithKline Pharmaceuticals
NSI:GLAXO
53
CountryUK
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
DiaSorin
MIL:DIA
34
CountryItaly
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →